Loading…
Technology targets diabetes remission and potential complete cure.
Visionary Holdings Inc. (XNAS: GV) has secured a global license for a breakthrough stem cell technology aimed at achieving diabetes remission and potentially a complete cure. The technology, valued at USD 150 billion, represents a significant advancement in the treatment of diabetes.
The license grants Visionary Holdings exclusive rights to utilize and develop the stem cell technology globally. This development is expected to enhance the company's portfolio in the education and training services sector, particularly in the field of medical and scientific training.
Visionary Holdings has a free float of 1,678,400 shares and 4,090,700 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.